- Home
- ACT vs PCVX Comparison
ACT vs PCVX Comparison
Compare ACT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACT | PCVX |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACT | PCVX |
|---|---|---|
| Price | $43.07 | $54.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $42.67 | ★ $97.67 |
| AVG Volume (30 Days) | 344.9K | ★ 1.6M |
| Earning Date | 02-03-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 3.43 | N/A |
| EPS | ★ 4.52 | N/A |
| Revenue | ★ $1,235,827,000.00 | N/A |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | $9.41 | ★ N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $31.28 | $27.66 |
| 52 Week High | $44.80 | $87.42 |
Technical Indicators
Market Signals| Indicator | ACT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 63.94 | 56.56 |
| Support Level | $42.01 | $53.12 |
| Resistance Level | $44.80 | $58.00 |
| Average True Range (ATR) | 1.15 | 3.35 |
| MACD | 0.32 | -0.09 |
| Stochastic Oscillator | 74.76 | 43.08 |
Price Performance
Historical ComparisonAbout ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.